Dr. Joseph Albert Susi, M.D. Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 11221 Firethorn Rd, Wattsburg, PA 16442 Phone: 814-739-9206 |
News Archive
Using clever chemistry, a Scripps Research team has pinpointed the enzyme target of a drug group that stops the progression of the devastating disease Friedreich's ataxia in mice and may do the same for humans. The findings, developed in collaboration with scientists from Repligen Corporation, help advance this treatment approach one step closer toward human clinical trials, which will be a welcome event for disease sufferers who currently have few treatment options.
NPR reports that California's $26.3 billion budget deficit is marginalizing seniors who rely on California state-provided health care and service to help them manage their lives.
According to a study presented November 4, 2009, at the 51st Annual Meeting of the American Society for Radiation Oncology (ASTRO), a shortened, more intensive course of radiation given to the whole breast, along with an extra dose of radiation given to the surgical bed of the tumor (concomitant boost), has been shown to result in excellent local control at a median follow up of two years after treatment with no significant sides effects.
A new study demonstrates that sewage is an effective means to sample the fecal bacteria from millions of people. Researchers say the information gleaned from the work provides a unique opportunity to monitor, through gut microbes, the public health of a large population without compromising the privacy of individuals.
Aeolus Pharmaceuticals, Inc. announced today that after review of the Company's white paper on development of AEOL-10150 as a countermeasure for the lung effects of acute radiation syndrome, the Biomedical Advanced Research and Development Authority (BARDA) Division of Chemical, Radiological and Nuclear (CBRN) Countermeasures has informed the Company that, after careful analysis and consideration, it has invited Aeolus to submit a full proposal for a contract to develop AEOL 10150 from its current level of technical readiness to FDA approval.
› Verified 7 days ago